Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Conceptus (CPTS) -- Ignore unavailable to you. Want to Upgrade?

To: telephonics who wrote (76)	11/9/2005 10:37:38 AM
From: tuck	Read Replies (1) \| Respond to of 96

>>SAN CARLOS, Calif., Nov. 9 /PRNewswire-FirstCall/ -- New data being presented this week at the American Association of Gynecologic Laparoscopists' (AAGL) annual meeting in Chicago confirms hysteroscopic sterilization can successfully be performed in an office setting with minimal anesthesia using the Essure® procedure from Conceptus, Inc. (Nasdaq: CPTS - News) giving both gynecologists and their patients a safe choice in permanent birth control. More than a dozen scientific presentations at the conference will cover topics such as hysteroscopic sterilization under local anesthesia and long-term safety and efficiency of the Essure system. The Essure Permanent Birth Control system achieves tubal sterilization through hysteroscopic placement of micro-inserts in the fallopian tubes. The various presentations discuss success rates of initial placement and permanent occlusion of the Essure device, pain scores and procedure satisfaction ratings. The data also indicates that offering the Essure procedure in the office setting is convenient and cost effective for both patients and physicians. "The data presented at AAGL validates that the Essure procedure can be successfully adopted into the commercial office setting," Mark Sieczkarek, president and CEO of Conceptus, said. "We are proud to offer clinicians and their patients a non-incisional and more convenient alternative to traditional tubal ligation." Physicians polled by Contemporary OB/GYN cited the Essure procedure as one of the top five technologies that will impact their practices in the future. Presentations at this year's AAGL conference include: Professor's Round Table Luncheon Wednesday, November 9, 11:45 a.m. - 12:45 p.m. Hysteroscopic Sterilization in the Office Amy L. Garcia Open Communications 3 Thursday, November 10, 3:45 p.m. - 5:15 p.m. Hysteroscopic Placement of Essure Device in an Office Setting Under Local Anesthesia: Successful Placement and Occlusion Rates M.D. Levie, S. Chudnoff Plenary 10 Friday, November 11, 10:30 a.m. - 11:30 a.m. Office Hysteroscopic Sterilization Compared to Laparoscopic Sterilization: A Critical Cost Analysis M.D. Levie, S. Chudnoff Hysteroscopic Sterilization: Long-Term Safety and Efficacy J.F. Kerin Hysteroscopic Sterilization with Essure in an Office Setting Under Local Anesthesia: Patient Assessment of Procedural Pain and Satisfaction S. Chudnoff, M.D. Levie, B. Levy, D. Snyder Surgical Tutorial Friday, November 11, 10:30 a.m. - 11:00 a.m. Hysteroscopic Sterilization James B. Presthus and David J. Levine Surgical Crossfire Debate 6 Saturday, November 12, 2:15 p.m. - 3:30 p.m. Resolved: Hysteroscopic Sterilization Will Replace the Laparoscopic Approach Jacques E. Rioux, Chair, Pro - Robert K. Zurawin, Con - G. Marcus Filshie Scientific Videos Session 6 Friday, November 11, 11:30 a.m. - 12:30 p.m. Office Based Hysteroscopic Sterilization S. Chudnoff , M.D. Levie, J. Lopez Additional educational presentations will take place at Conceptus booth #1010 at the Hilton Chicago, 720 South Michigan Avenue. About the Essure® Procedure The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80 percent effective after four years of follow-up. The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74 percent effective based on five years of follow-up. Five-year follow-up of all patients in clinical trials is ongoing.<< snip A little more timely for ya? Cheers, Tuck